You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Covid jabs for kids in 2-11 age group: Pfizer to seek approval in Sep

Pfizer will likely seek the US Food and Drug Administration's emergency authorisation to administer its coronavirus vaccine among children between the ages of 2 and 11 in September, media reports

Coronavirus Vaccine | Pfizer | Vaccination

IANS  |  Washington 

Pfizer Vaccine, Coronavirus vaccine
Photo: Shutterstock

Pharmaceutical major will likely seek the US Food and Drug Administration's emergency authorisation to administer its among children between the ages of 2 and 11 in September, the media reported.

By early next week, the company is expected to get FDA approval for emergency use of its vaccine in children 12 to 15 years old.

It is planning to apply for full approval of the vaccine for use in people from ages 16 to 85, this month, The New York Times reported. The pharma major will also have clinical trial data on the safety of its vaccine in pregnant women by early August.

The FDA is preparing to make Covid vaccines "accessible to additional, younger populations", Jen Psaki, the White House press secretary, was quoted as saying at a news conference on Tuesday, the report said.

Currently, the Pfizer-BioNTech vaccine is given to adults under an emergency use authorization that the companies received in December. Obtaining full FDA approval will allow it to market the vaccine directly to consumers.

"Full approval is a welcome indicator of the continued safety and efficacy of the vaccine," Saskia Popescu, an infectious disease epidemiologist at George Mason University, was quoted as saying.

Earlier in March, results of a clinical trial led by the companies showed that the Pfizer-BioNTech is extremely effective in young adolescents, even more than in adults. The children produced strong antibody responses and experienced no serious side effects.

Vaccinating adolescents may also be key to boost immunity levels in the general population and thus reduce the number of hospitalisation and death.

A full approval may also make it easier for companies, government agencies, schools to get vaccinated and the jabs will stay in the market, even after the end of the pandemic, the report said.




(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, May 05 2021. 12:30 IST